Seminal plasma characteristics as indicators of cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in men with obstructive azoospermia

Citation
S. Von Eckardstein et al., Seminal plasma characteristics as indicators of cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in men with obstructive azoospermia, FERT STERIL, 73(6), 2000, pp. 1226-1231
Citations number
34
Categorie Soggetti
Reproductive Medicine","da verificare
Journal title
FERTILITY AND STERILITY
ISSN journal
00150282 → ACNP
Volume
73
Issue
6
Year of publication
2000
Pages
1226 - 1231
Database
ISI
SICI code
0015-0282(200006)73:6<1226:SPCAIO>2.0.ZU;2-X
Abstract
Objective: To determine the prognostic value of seminal plasma volume, pH, fructase, and alpha-glucosidase for the detection of cystic fibrosis transm embrane conductance regulator (CFTR) gene mutations. Design: Retrospective data analysis. Setting: University infertility clinic (referral center). Patient(s): Fifty-nine men with obstructive azoospermia. Intervention(s): S emen analysis including seminal plasma volume, pH, fructose, alpha-glucosid ase, molecular genetic diagnosis of CFTR mutations and FSH measurement. Main Outcome Measure(s): Sensitivity and specificity of seminal plasma mark ers for the detection of CFTR mutations. Result(s): A CFTR mutation was detected in 26 of 59 patients with obstructi ve azoospermia. Patients carrying a mutation had significantly lower semina l plasma volume (mean +/- SEM: 1.5 +/- 1.4 mL, vs. 2.8 +/- 2.2 mL), lower p H levels (25th percentile, median, 75th percentile: 6.5, 6.8, 7.5 vs. 7.7, 7.9, 7.9) and lower fructose content (1.0, 1.1, 3.7 vs. 5.8, 20.0, 83.0 mu mol/ejaculate) than those without mutations. Diagnostic efficacy for detect ion of mutations was best (pH 81.4%, fructose 81.8%) at a cutoff level for pH of 7.4 and fructose of 2 mu mol/ejaculate. Conclusion(s): Seminal plasma markers provide an effective, noninvasive met hod to predict CFTR mutations in men with obstructive azoospermia. ((C) 200 0 by American Society for Reproductive Medicine.)